Bolt Biotherapeutics Profit Margin

The latest profit margin for BOLT is -611.47% as of June 2026. That compares with -1217.01% in the prior-year period — up 49.8% year over year. That is below the Healthcare sector average of 13.45%. Investors often review this figure alongside Bolt Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BOLT's profit margin moved from -1217.01% to -611.47% — a 49.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bolt Biotherapeutics's valuation or profitability profile.

Against Healthcare companies, BOLT currently prints -611.47% for profit margin, while the sector average sits near 13.45%. That is roughly 4647.0% below the sector mean. Large gaps often invite a closer look at Bolt Biotherapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Bolt Biotherapeutics converts resources into returns. At -611.47%, BOLT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1217.01% in the prior-year period — up 49.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BOLT's profit margin (-611.47%), review year-over-year change from -1217.01%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.